Clinical trial
Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
NCT00473083 · British Columbia Cancer Agency, Other · Completed
Key facts
| NCT number | NCT00473083 |
|---|---|
| Title | Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer |
| Official title | A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer |
| Acronym | LUTRAERL |
| Lead sponsor | British Columbia Cancer Agency, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rash |
| Intervention type | Drug |
| Interventions | Minocycline, Clindamycin 2% in hydrocortisone 1% lotion, Erlotinib, Topical clindamycin 2%, triamcinolone acetonide 0.1% soln |
| Enrollment | 150 |
| Start date | Jan 1, 2009 |
| Primary completion | Dec 1, 2012 |
| Completion | Aug 1, 2013 |
| First posted | May 14, 2007 |
| Last update posted | Apr 4, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: